13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001281446
Total reported value
$529.1M
$529.1M
26 檔
12.9%
During the Q2 2025 filing period, Great Point Partners LLC (CIK: 0001281446) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $529.1M across 26 reported positions.
In Q2 2025, Great Point Partners LLC adopted a defensive or profit-taking posture, trimming 8 positions and completely liquidating 12 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 12.84% | — | +100.00% | |
| 2 | RZLT | Rezolute Inc | Stock-Other | 8.80% | +0.27% | +264.14% | |
| 3 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 8.34% | -3.21% | +10.38% | |
| 4 | LEGN | Legend Biotech Corp-adr | Stock-Other | 8.08% | — | +153.18% | |
| 5 | ABVX | Abivax Sa-adr | Stock-Other | 6.42% | +15.22% | NEW | |
| 6 | NGNE | Neurogene Inc | Stock-Other | 4.72% | -0.23% | +3.16% | |
| 7 | AKBA | Akebia Therapeutics Inc | Stock-Other | 4.70% | — | -60.07% | |
| 8 | EOLS | Evolus Inc | Stock-Other | 4.31% | — | -23.78% | |
| 9 | ACLXGBX | Arcellx Inc | Stock-Other | 4.28% | — | +122.22% | |
| 10 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 4.07% | — | -18.46% | |
| 11 | AKRO | Akero Therapeutics Inc | Stock-Other | 3.60% | — | — | |
| 12 | JBIO | Jade Biosciences Inc | Stock-Other | 3.24% | -3.11% | EXIT | |
| 13 | CYTK | Cytokinetics Inc | Stock-Healthcare | 3.22% | — | -59.46% | |
| 14 | IMVT | Immunovant Inc | Stock-Other | 2.73% | -3.11% | EXIT | |
| 15 | UNCY | Unicycive Therapeutics Inc | Stock-Other | 2.47% | -1.20% | EXIT | |
| 16 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 2.38% | -3.12% | EXIT | |
| 17 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 2.25% | — | — | |
| 18 | DBVT | Dbv Technologies Sa-spon Adr | Stock-Other | 2.23% | +0.49% | NEW | |
| 19 | ✓ | Zura Bio LTD | Stock-Other | 2.16% | -1.07% | — | |
| 20 | UPB | Upstream Bio Inc | Stock-Other | 2.14% | — | — | |
| 21 | CNTX | Context Therapeutics Inc | Stock-Other | 2.00% | -1.35% | EXIT | |
| 22 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.92% | — | +50.30% | |
| 23 | SRRK | Scholar Rock Holding CORP | Stock-Other | 1.42% | — | — | |
| 24 | PMNEUR | Promis Neurosciences Inc | Stock-Other | 0.83% | — | — | |
| 25 | PLRX | Pliant Therapeutics Inc | Stock-Other | 0.64% | — | — | |
| 26 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 0.20% | — | -92.14% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | IONS | Ionis Pharmaceuticals Inc | +8.8% | +100.00% | Add |
| 2 | RZLT | Rezolute Inc | +7.5% | +264.14% | Add |
| 3 | LEGN | Legend Biotech Corp-adr | +5.6% | +153.18% | Add |
| 4 | AMLX | Amylyx Pharmaceuticals Inc | +4.9% | +10.38% | Add |
| 5 | AKRO | Akero Therapeutics Inc | +3.6% | NEW | New buy |
| 6 | JBIO | Jade Biosciences Inc | +3.2% | NEW | New buy |
| 7 | ACLXGBX | Arcellx Inc | +2.7% | +122.22% | Add |
| 8 | UNCY | Unicycive Therapeutics Inc | +2.5% | NEW | New buy |
| 9 | TSHA | Taysha Gene Therapies Inc | +2.3% | NEW | New buy |
| 10 | DBVT | Dbv Technologies Sa-spon Adr | +2.2% | NEW | New buy |
| 11 | NGNE | Neurogene Inc | +1.8% | +3.16% | Add |
| 12 | SRRK | Scholar Rock Holding CORP | +1.4% | NEW | New buy |
| 13 | UPB | Upstream Bio Inc | +1.2% | — | Unchanged |
| 14 | ABVX | Abivax Sa-adr | +1% | -21.15% | Trim |
| 15 | 260 | Centessa Pharmaceuticals-adr | +0.8% | +50.30% | Add |
| 16 | CNTX | Context Therapeutics Inc | +0.5% | — | Unchanged |
| 17 | PLRX | Pliant Therapeutics Inc | 0% | — | Unchanged |
| 18 | ✓ | Zura Bio LTD | 0% | — | Unchanged |
| 19 | PMNEUR | Promis Neurosciences Inc | -0.1% | — | Unchanged |
| 20 | XENE | Xenon Pharmaceuticals Inc | -0.3% | -18.46% | Trim |
| 21 | AKBA | Akebia Therapeutics Inc | -0.4% | -60.07% | Trim |
| 22 | IMVT | Immunovant Inc | -0.7% | -30.09% | Trim |
| 23 | VYGR | Voyager Therapeutics Inc | -1.1% | EXIT | Sold out |
| 24 | MREO | Mereo Biopharma Group Pl-adr | -1.5% | EXIT | Sold out |
| 25 | EOLS | Evolus Inc | -1.7% | -23.78% | Trim |
| 26 | BEAM | Beam Therapeutics Inc | -1.8% | EXIT | Sold out |
| 27 | ✓ | Helix Acquisition CORP Ii | -2% | -92.14% | Trim |
| 28 | AUTL | Autolus Therapeutics PLC | -2.2% | EXIT | Sold out |
| 29 | PCVX | Vaxcyte Inc | -2.3% | EXIT | Sold out |
| 30 | SMMT | Summit Therapeutics Inc | -2.6% | EXIT | Sold out |
| 31 | DNTH | Dianthus Therapeutics Inc | -2.6% | EXIT | Sold out |
| 32 | ✓ | -3.3% | EXIT | Sold out | |
| 33 | 4XC1 | Kalvista Pharmaceuticals Inc | -3.8% | -68.14% | Trim |
| 34 | DVAX | Dynavax Technologies CORP | -4.1% | EXIT | Sold out |
| 35 | ASND | Ascendis Pharma A/S | -4.1% | EXIT | Sold out |
| 36 | CYTK | Cytokinetics Inc | -4.7% | -59.46% | Trim |
| 37 | ✓ | Merus N V | -5.3% | EXIT | Sold out |
| 38 | VRDN | Viridian Therapeutics Inc | -5.4% | EXIT | Sold out |
According to official SEC Form 13F filings, Great Point Partners LLC reported a total U.S. public equity portfolio value of $529.1M across 26 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including IONS, RZLT, AMLX) accounted for 12.9% of total reported equity market value during Q2 2025.
Top New Position Initiated
AKRO
市值: $5.5M
Top Position Liquidated / Trimmed
VRDN
前期市值: $10.1M
During Q2 2025, Great Point Partners LLC's top holdings by market value included IONS (12.8%)、RZLT (8.8%)、AMLX (8.3%). The largest single position, IONS, represented 12.8% of total portfolio value.
In Q2 2025, Great Point Partners LLC made 33 total portfolio adjustments, initiating 6 new buys, adding to 7 positions, trimming 8 holdings, and fully liquidating 12 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.